Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke

Brain

Volumn 134, Issue 6, 2011, Pages 1790-1807

  Honmou, Osamu ^a,b,c   Houkin, Kiyohiro ^a   Matsunaga, Takuya ^a   Niitsu, Yoshiro ^a   Ishiai, Sumio ^a   Onodera, Rie ^a   Waxman, Stephen G ^b,c   Kocsis, Jeffery D ^b,c  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

bone marrow derived stem cells; cell transplantation; cerebrovascular disease; mesenchymal stem cells; stem cell; stroke

Indexed keywords

PLACEBO;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN DAMAGE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DETERIORATION; FEMALE; FETAL CALF SERUM; GRAY MATTER; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INFUSION; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEOPLASM; NERVE CELL GROWTH; NEUROLOGIC DISEASE; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; PRIORITY JOURNAL; RANKIN SCALE; SAFETY; SCORING SYSTEM; SERUM; SPEECH THERAPY; STROKE; SYSTEMIC DISEASE; TRACTOGRAPHY; VENOUS THROMBOEMBOLISM; WHITE MATTER;

ADULT; AGED; BRAIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; NEUROLOGIC EXAMINATION; SEVERITY OF ILLNESS INDEX; STROKE; TIME FACTORS; TISSUE THERAPY; TRANSPLANTATION, AUTOLOGOUS;

EID: 79957796744     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr063     Document Type: Article

References (44)

1. Abe K, Hayashi T, Itoyama Y. Amelioration of brain edema by topical application of glial cell line-derived neurotrophic factor in reperfused rat brain. Neurosci Lett 1997; 231: 37-40. (Pubitemid 27366283)
2. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005; 57: 874-82. (Pubitemid 40798626)
3. Boulenguez P, Liabeuf S, Bos R, Bras H, Jean-Xavier C, Brocard C, et al. Down-regulation of the potassium-chloride cotransporter KCC2 contributes to spasticity after spinal cord injury. Nat Med 2010; 16: 302-7.
4. Chen J, Li Y, Wang L, Lu M, Zhang X, Chopp M. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci 2001; 189: 49-57. (Pubitemid 32776649)
5. Chen J, Zhang ZG, Li Y, Wang L, Xu YX, Gautam SC, et al. Intravenous administration of human bone marrow stromal cells induces angiogen-esis in the ischemic boundary zone after stroke in rats. Circ Res 2003; 92: 692-9. (Pubitemid 36417705)
6. Chopp M, Li Y. Treatment of neural injury with marrow stromal cells. Lancet Neurol 2002; 1: 92-100. (Pubitemid 37163494)
7. Drach G, Maret A, Richard MF, Barbu E. [Transfer and induction of delayed hypersensitivity to methylated bovine serum albumin in the absence of adjuvant]. C R Acad Sci Hebd Seances Acad Sci D 1977; 284: 2435-7.
8. Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, Wood S, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005; 352: 2069-81. (Pubitemid 40664308)
9. Freedman MS, Bar-Or A, Atkins HL, Karussis D, Frassoni F, Lazarus H, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler 2010; 16: 503-10.
10. Gaudinski MR, Henning EC, Miracle A, Luby M, Warach S, Latour L. Establishing final infarct volume: stroke lesion evolution past 30 days is significant. Stroke 2008; 39: 2765-8.
11. Gordon D, Scolding NJ. Human mesenchymal stem cell culture for neural transplantation. Methods Mol Biol 2009; 549: 103-18.
12. Honma T, Honmou O, Iihoshi S, Harada K, Houkin K, Hamada H, et al. Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Exp Neurol 2006; 199: 56-66.
13. Honmou O, Houkin K, Matsunaka T, Niitsu Y, Ishiai S, Waxman SG, et al. Intravenous transplantation of autologous mesenchymal stem cells derived from bone marrow into stroke patients. Stroke 2008; 39: 543.
14. Horita Y, Honmou O, Harada K, Houkin K, Hamada H, Kocsis JD. Intravenous administration of glial cell line-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in the adult rat. J Neurosci Res 2006; 84: 1495-504. (Pubitemid 44683142)
15. Kim S, Honmou O, Kato K, Nonaka T, Houkin K, Hamada H, et al. Neural differentiation potential of peripheral blood- and bone-marrow-derived precursor cells. Brain Res 2006; 1123: 27-33.
16. Kobayashi T, Watanabe H, Yanagawa T, Tsutsumi S, Kayakabe M, Shinozaki T, et al. Motility and growth of human bone-marrow mes-enchymal stem cells during ex vivo expansion in autologous serum. J Bone Joint Surg Br 2005; 87: 1426-33. (Pubitemid 41511812)
17. Kobune M, Kawano Y, Ito Y, Chiba H, Nakamura K, Tsuda H, et al. Telomerized human multipotent mesenchymal cells can differentiate into hematopoietic and cobblestone area-supporting cells. Exp Hematol 2003; 31: 715-22. (Pubitemid 36945385)
18. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leu-kodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002; 30: 215-22. (Pubitemid 35023593)
19. Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchy-mal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307-16. (Pubitemid 30056419)
20. Komatsu K, Honmou O, Suzuki J, Houkin K, Hamada H, Kocsis JD. Therapeutic time window of mesenchymal stem cells derived from bone marrow after cerebral ischemia. Brain Res 2010; 1334: 84-92.
21. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389-98. (Pubitemid 40542932)
22. Levine ES, Crozier RA, Black IB, Plummer MR. Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-D-aspartic acid receptor activity. Proc Natl Acad Sci USA 1998; 95: 10235-9. (Pubitemid 28415324)
23. Li Y, Chen J, Chen XG, Wang L, Gautam SC, Xu YX, et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 2002; 59: 514-23. (Pubitemid 34919983)
24. Liu H, Honmou O, Harada K, Nakamura K, Houkin K, Hamada H, et al. Neuroprotection by PlGF gene-modified human mesenchymal stem cells after cerebral ischaemia. Brain 2006; 129: 2734-45. (Pubitemid 44522106)
25. Mizoguchi Y, Monji A, Nabekura J. Brain-derived neurotrophic factor induces long-lasting Ca2 +-activated K+ currents in rat visual cortex neurons. Eur J Neurosci 2002; 16: 1417-24. (Pubitemid 35334978)
26. Neumann-Haefelin T, Kastrup A, de Crespigny A, Yenari MA, Ringer T, et al. Serial MRI after transient focal cerebral ischemia in rats: dynamics of tissue injury, blood-brain barrier damage, and edema formation. Stroke 2000; 31: 1965-72.
27. Nomura T, Honmou O, Harada K, Houkin K, Hamada H, Kocsis JD. I.V. infusion of brain-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Neuroscience 2005; 136: 161-9. (Pubitemid 41483844)
28. Ohta T, Kikuchi H, Hashi K, Kudo Y. Nizofenone administration in the acute stage following subarachnoid hemorrhage. Results of a multi-center controlled double-blind clinical study. J Neurosurg 1986; 64: 420-6. (Pubitemid 16035064)
29. Ohtaki H, Ylostalo JH, Foraker JE, Robinson AP, Reger RL, Shioda S, et al. Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci USA 2008; 105: 14638-43.
30. Omori Y, Honmou O, Harada K, Suzuki J, Houkin K, Kocsis JD. Optimization of a therapeutic protocol for intravenous injection of human mesenchymal stem cells after cerebral ischemia in adult rats. Brain Res 2008; 1236: 30-8.
31. Onda T, Honmou O, Harada K, Houkin K, Hamada H, Kocsis JD. Therapeutic benefits by human mesenchymal stem cells (hMSCs) and Ang-1 gene-modified hMSCs after cerebral ischemia. J Cereb Blood Flow Metab 2008; 28: 329-40. (Pubitemid 351161284)
32. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71-4. (Pubitemid 27161245)
33. Prockop DJ. "Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin Pharmacol Ther 2007; 82: 241-3. (Pubitemid 47258475)
34. Rogalski SL, Appleyard SM, Pattillo A, Terman GW, Chavkin C. TrkB activation by brain-derived neurotrophic factor inhibits the G protein-gated inward rectifier Kir3 by tyrosine phosphorylation of the channel. J Biol Chem 2000; 275: 25082-8.
35. Scolding N, Marks D, Rice C. Autologous mesenchymal bone marrow stem cells: practical considerations. J Neurol Sci 2008; 265: 111-5.
36. Shahdadfar A, Fronsdal K, Haug T, Reinholt FP, Brinchmann JE. In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 2005; 23: 1357-66. (Pubitemid 41504923)
37. Sharma HS. Neurotrophic factors attenuate microvascular permeability disturbances and axonal injury following trauma to the rat spinal cord. Acta Neurochir Suppl 2003; 86: 383-8.
38. Sharma HS, Johanson CE. Intracerebroventricularly administered neuro-trophins attenuate blood cerebrospinal fluid barrier breakdown and brain pathology following whole-body hyperthermia: an experimental study in the rat using biochemical and morphological approaches. Ann NY Acad Sci 2007; 1122: 112-29.
39. Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004; 9: 747-56. (Pubitemid 38660428)
40. Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P, et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004; 350: 1960-9. (Pubitemid 38580199)
41. Toyama K, Honmou O, Harada K, Suzuki J, Houkin K, Hamada H, et al. Therapeutic benefits of angiogenetic gene-modified human mesenchy-mal stem cells after cerebral ischemia. Exp Neurol 2009; 216: 47-55.
42. Tucker K, Fadool DA. Neurotrophin modulation of voltage-gated potassium channels in rat through TrkB receptors is time and sensory experience dependent. J Physiol 2002; 542: 413-29. (Pubitemid 35190304)
43. Ukai R, Honmou O, Harada K, Houkin K, Hamada H, Kocsis JD. Mesenchymal stem cells derived from peripheral blood protects against ischemia. J Neurotrauma 2007; 24: 508-20. (Pubitemid 46598284)
44. Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 2000; 61: 364-70. (Pubitemid 30620221)